The general manager of Bioiberica highlighted his companys commitment to a comprehensive approach to the treatment of osteoarthritis: prevention, chondroprotector drugs, and personalized medicine. Together, all these elements improve the patients quality of life.
For further information, go to:
http://www.correofarmaceutico.com/2011/10/17/farmacologia/estamos-estupefactos-ante-el-desamparo-en-artrosis
http://www.correofarmaceutico.com/2011/10/17/farmacologia/debemos-aceptar-las-nuevas-reglas-del-juego-y-buscar-oportunidades-entre-ellas
As Bioiberica celebrates its 50th anniversary, Luis Solera, CEO reflects on the company’s evolution—from a pioneer in heparin production to a global leader in the biotech industry.